The content on this site is intended for healthcare professionals only
Dr Flaherty BRAF inhibitors as a strategy for the treatment of metastatic melanoma at the Society for Melanoma Research (SMR) International Congress 2014 in Switzerland.
See also:
BRAF 'behind the scenes' in melanoma: A scientific story of discovery
GSK has paid for the organisation costs of the symposium and honoraria for the chairperson and speakers. GSK has contributed to the agenda and content of the meeting.
Zinc code: OF/ONC/0003/15d
Date of preparation: February 2015
EGFR shows to be a promising therapeutic target in NF1 mutant melanoma
ELCC 2025: Latest in EGFR positive NSCLC
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Advancements in paediatric Acute lymphoblastic leukemia management
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Choosing 1st line TKI Wisely in patients with CML
ESMO 2024: Latest in EGFR mutated NSCLC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
